KR102490961B1 - 뇌암의 치료 - Google Patents

뇌암의 치료 Download PDF

Info

Publication number
KR102490961B1
KR102490961B1 KR1020217033686A KR20217033686A KR102490961B1 KR 102490961 B1 KR102490961 B1 KR 102490961B1 KR 1020217033686 A KR1020217033686 A KR 1020217033686A KR 20217033686 A KR20217033686 A KR 20217033686A KR 102490961 B1 KR102490961 B1 KR 102490961B1
Authority
KR
South Korea
Prior art keywords
certain embodiments
yloxy
methylphenyl
pyridin
dihydrooxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217033686A
Other languages
English (en)
Korean (ko)
Other versions
KR20210131426A (ko
Inventor
파트리스 에이. 리
새넌 엘. 윈스키
케빈 코치
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102490961(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20210131426A publication Critical patent/KR20210131426A/ko
Application granted granted Critical
Publication of KR102490961B1 publication Critical patent/KR102490961B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020217033686A 2012-03-23 2013-03-25 뇌암의 치료 Active KR102490961B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
US61/615,082 2012-03-23
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer
KR1020207027176A KR102317166B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207027176A Division KR102317166B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료

Publications (2)

Publication Number Publication Date
KR20210131426A KR20210131426A (ko) 2021-11-02
KR102490961B1 true KR102490961B1 (ko) 2023-01-19

Family

ID=48048296

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217033686A Active KR102490961B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료
KR1020147029340A Active KR102160462B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료
KR1020207027176A Active KR102317166B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147029340A Active KR102160462B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료
KR1020207027176A Active KR102317166B1 (ko) 2012-03-23 2013-03-25 뇌암의 치료

Country Status (30)

Country Link
US (3) US20150110780A1 (https=)
EP (4) EP4252855A3 (https=)
JP (6) JP2015514075A (https=)
KR (3) KR102490961B1 (https=)
CN (2) CN104203279B (https=)
AU (4) AU2013234921A1 (https=)
CA (1) CA2867723C (https=)
CL (1) CL2014002497A1 (https=)
CO (1) CO7071139A2 (https=)
CY (2) CY1120204T1 (https=)
DK (2) DK3400943T3 (https=)
ES (2) ES2673165T3 (https=)
HR (1) HRP20180659T1 (https=)
HU (2) HUE053156T2 (https=)
IL (3) IL234627B (https=)
LT (1) LT2827900T (https=)
MX (1) MX354024B (https=)
MY (2) MY202114A (https=)
NZ (4) NZ630843A (https=)
PH (2) PH12021550360A1 (https=)
PL (2) PL3400943T3 (https=)
PT (2) PT2827900T (https=)
RS (1) RS57140B1 (https=)
RU (2) RU2672575C2 (https=)
SG (1) SG11201405954YA (https=)
SI (2) SI2827900T1 (https=)
SM (1) SMT201800251T1 (https=)
TR (1) TR201808450T4 (https=)
UA (1) UA122044C2 (https=)
WO (1) WO2013142875A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
BR122020010643B1 (pt) 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
WO2013142875A1 (en) 2012-03-23 2013-09-26 Array Biopharma Inc. Treatment of brain cancer
US11078272B2 (en) 2017-03-09 2021-08-03 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of CD47 pathway
CA3060407A1 (en) 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
US11298422B2 (en) * 2018-04-09 2022-04-12 Novocure Gmbh Treating tumors with TTFields and an aurora kinase inhibitor
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
WO2001091794A2 (en) 2000-05-30 2001-12-06 Virginia Commonwealth University Vitamin d3 analogs as radiosensitizers for the treatment of cancer
WO2005016346A1 (en) 2003-08-14 2005-02-24 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆（科克）有限公司 癌症治疗方法
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
ES2364901T3 (es) 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
JP5068270B2 (ja) 2006-01-31 2012-11-07 ノバルティス アーゲー 癌を処置するためのｉｌ−１７アンタゴニスト抗体
CA2700673A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
NZ602675A (en) 2008-03-18 2014-03-28 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
BR122020010643B1 (pt) 2011-10-14 2022-05-17 Array Biopharma Inc Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
WO2013142875A1 (en) 2012-03-23 2013-09-26 Array Biopharma Inc. Treatment of brain cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kevin Koch, et al., ARRY-380: A selective, oral HER2 inhibitor for the treatment of solid tumors, American Association for Cancer Research Annual Meeting. (2011.04.03.)

Also Published As

Publication number Publication date
KR20200115656A (ko) 2020-10-07
CA2867723A1 (en) 2013-09-26
AU2021261849A1 (en) 2021-12-02
IL269205A (en) 2019-11-28
PT3400943T (pt) 2021-02-02
JP2019081792A (ja) 2019-05-30
CN104203279A (zh) 2014-12-10
JP2021178820A (ja) 2021-11-18
NZ630843A (en) 2017-01-27
KR20140139009A (ko) 2014-12-04
US20230190749A1 (en) 2023-06-22
HK1206276A1 (en) 2016-01-08
RU2014142700A (ru) 2016-05-20
EP4252855A3 (en) 2023-11-15
SMT201800251T1 (it) 2018-07-17
JP6898960B2 (ja) 2021-07-07
HUE037966T2 (hu) 2018-09-28
JP2022190126A (ja) 2022-12-22
HRP20180659T1 (hr) 2018-06-01
EP3400943B1 (en) 2020-12-02
SI2827900T1 (en) 2018-06-29
AU2019203618B2 (en) 2021-08-05
RU2018138976A3 (https=) 2022-04-08
CY1123837T1 (el) 2022-05-27
PL3400943T3 (pl) 2021-06-14
JP2024019526A (ja) 2024-02-09
PH12014502032A1 (en) 2014-11-24
ES2855142T3 (es) 2021-09-23
JP7404485B2 (ja) 2023-12-25
EP4252855A2 (en) 2023-10-04
AU2013234921A1 (en) 2014-10-02
CN104203279B (zh) 2018-10-30
DK2827900T3 (en) 2018-05-07
CA2867723C (en) 2022-11-08
NZ756264A (en) 2022-09-30
RS57140B1 (sr) 2018-07-31
CY1120204T1 (el) 2018-12-12
JP2015514075A (ja) 2015-05-18
AU2017272232C1 (en) 2019-08-15
TR201808450T4 (tr) 2018-07-23
EP2827900B1 (en) 2018-03-21
US20190255051A1 (en) 2019-08-22
NZ741615A (en) 2019-10-25
MY202114A (en) 2024-04-04
EP3842044A1 (en) 2021-06-30
ES2673165T3 (es) 2018-06-20
PH12021550360A1 (en) 2023-04-03
HUE053156T2 (hu) 2021-06-28
KR102160462B1 (ko) 2020-09-28
AU2017272232A1 (en) 2018-01-04
IL261659A (en) 2018-10-31
MY174883A (en) 2020-05-20
EP3400943A1 (en) 2018-11-14
SG11201405954YA (en) 2014-10-30
EP2827900A1 (en) 2015-01-28
DK3400943T3 (da) 2021-02-08
LT2827900T (lt) 2018-05-10
WO2013142875A1 (en) 2013-09-26
MX2014011437A (es) 2014-11-10
KR20210131426A (ko) 2021-11-02
PT2827900T (pt) 2018-06-14
AU2019203618A1 (en) 2019-06-13
US20150110780A1 (en) 2015-04-23
JP2017141302A (ja) 2017-08-17
SI3400943T1 (sl) 2021-03-31
IL269205B (en) 2020-06-30
IL234627B (en) 2018-10-31
MX354024B (es) 2018-02-08
PL2827900T3 (pl) 2018-08-31
US11504370B2 (en) 2022-11-22
CL2014002497A1 (es) 2014-11-14
CO7071139A2 (es) 2014-09-30
KR102317166B1 (ko) 2021-10-26
RU2672575C2 (ru) 2018-11-16
RU2018138976A (ru) 2018-12-06
NZ724544A (en) 2018-05-25
UA122044C2 (uk) 2020-09-10
AU2017272232B2 (en) 2019-02-28
CN109223791A (zh) 2019-01-18

Similar Documents

Publication Publication Date Title
KR102490961B1 (ko) 뇌암의 치료
HK40102024A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40055793A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40000406A (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK40000406B (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
HK1206276B (en) Amorphous solid dispersion for use in the treatment of brain cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 3, Claim Number : 1 3, Period Limitation Text : 319, Comment Text : 183, 184

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 3, Claim Number : 1 3, Period Limitation Text : 319, Comment Text : 183, 184

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4